Azevan Pharmaceuticals

Azevan Pharmaceuticals, Inc. is a clinical-stage small molecule drug development company focused on developing therapeutic agents for stress, mood, and behavioral disorders. The company concentrates on clinical compounds that selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of major depressive disorder, intermittent explosive disorder, impulse control/anger management disorders, and post-traumatic stress disorder (PTSD). Its products include orally bioavailable SRX251 and SRX246, CNS-penetrating V1a receptor antagonists. The company’s SRX246 and SRX251 are being developed for stress-related central nervous system disorders, including depression, PTSD, and intermittent explosive disorder. Azevan Pharmaceuticals, Inc. was formerly known as Serenix Pharmaceuticals, LLC and changed its name to Azevan Pharmaceuticals, Inc.